literature

HIV mutation literature information.

Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.

PMID: 15855527 2005 Antimicrobial agents and chemotherapy

Abstract: K45R and K20T, which were associated with nelfinavir treatment, were specifically associated with D30N and N88D and with L90M, respectively.

Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs.

PMID: 16386116 2005 AIDS research and human retroviruses

Abstract: Two strains bore one major resistance mutation to PIs: M46I and N88D.

Short communication. Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa).

PMID: 16312182 2005 Antiviral therapy

Abstract: A few strains displayed primary mutations (the non-nucleoside reverse transcriptase inhibitor [NNRTI]-associated mutations K101E, K103T, L100I and G190V; the PI-associated mutation N88D; and the NRTI-associated mutation K65R).

Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.

PMID: 16851048 2005 The journal of physical chemistry. B

Abstract: N88D mutation

Abstract: Among patients who failed in the inhibitor nelfinavir (NFV) treatment, D30N, N88D, and L90M mutations of HIV-1 protease are often observed.

Abstract: Despite the serious clinical problem, it is not clear how these mutations, especially nonactive site mutations N88D and L90M, affect the affinity of NFV or why they cause the resistance to NFV.

Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.

PMID: 19825125 2005 Journal of the International AIDS Society

Table: N88D

Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.

PMID: 15168798 2004 Antiviral research

Abstract: By contrast, the half lives (t(1/2)) of the D30N and N88D mutations associated with nelfinavir (NFV) resistance were only 7.2 and 1.8 days, respectively.

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

PMID: 15155216 2004 Antimicrobial agents and chemotherapy

Abstract: Other mutations were L10I/V, K20R, M46I, V82A/I, I84V, N88D, and N88S.

Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

PMID: 12534958 2003 HIV medicine

Abstract: A pronounced accumulation of the secondary protease mutations N88D, M36I, and A71V/T was found, and D30N was strongly associated with N88D.

Abstract: Of eight patients with N88D, seven also harboured D30N (P < 0.01).

HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

PMID: 12741623 2003 Antiviral therapy

Abstract: Mutations D30N, G48V, N88D/S, L90M and 154V were de-selected, and mutations I50V, I or V to 54M/L, I84V, M46I/L, L33F, I47V as well mutations at position 10 were observed in 20/49 (41%) isolates.

Prevalence and virologic consequences of HIV-1 genotype mutations detected in a cohort of 161 Italian patients receiving a nelfinavir-based highly active antiretroviral therapy.

PMID: 12797395 2003 Journal of chemotherapy (Florence, Italy)

Abstract: On the whole, only 11 patients (7%) developed the D30N substitution, whose 6 was in association with the N88D mutation.

Browser Board

Co-occurred Entities

Filtrator